Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
304 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
Rank Status Study
21 Completed
Has Results
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Condition: Patent Ductus Arteriosus (PDA)
Interventions: Device: Device closure with AMPLATZER Duct Occluder;   Other: Objective Performance Criteria
22 Recruiting An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
Condition: Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Intervention: Drug: Triheptanoin
23 Completed
Has Results
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Natural Killer Cell Lymphoblastic Leukemia/Lymphoma
Interventions: Biological: Single Umbilical Cord Blood Unit Transplant;   Biological: Double Umbilical Cord Blood Unit Transplant;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine A;   Drug: Mycophenolate Mofetil
24 Recruiting CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Condition: Congenital Hyperinsulinism
Interventions: Drug: Glucagon;   Other: Placebo
25 Available Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
Condition: Parenteral Nutrition-Associated Liver Disease
Intervention: Drug: Omegaven
26 Recruiting Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL
Conditions: ALL, Childhood;   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Leukemia, Acute
Intervention: Drug: Marqibo in combination with UK ALL R3
27 Available Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Deflazacort
28 Active, not recruiting Study of N91115 in Patients With CF Homozygous for the F508del-CFTR Mutation
Condition: Cystic Fibrosis
Interventions: Drug: N91115;   Drug: Placebo
29 Recruiting Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Condition: Recurrent Osteosarcoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
30 Recruiting Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Conditions: Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
Interventions: Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
31 Recruiting Evaluation of Human Milk Fortifiers in Preterm Infants
Condition: Infant Growth
Interventions: Other: Human Milk Fortifier A;   Other: Human Milk Fortifier B
32 Recruiting Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
33 Recruiting Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
Condition: Persistent Pulmonary Hypertension of the Newborn
Interventions: Drug: IV Remodulin;   Drug: Placebo
34 Available Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies
Conditions: Dravet Syndrome;   Epileptic Encephalopathies Associated With SCN1A Mutations
Intervention: Drug: Stiripentol
35 Recruiting Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndrome (MDS);   Mixed Phenotype Acute Leukemia (MPAL)
Interventions: Drug: Selinexor;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: methotrexate/hydrocortisone/cytarabine
36 Recruiting Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Conditions: Adult Fibrosarcoma;   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
37 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
38 Active, not recruiting Long-term Safety and Efficacy of Lubiprostone in Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Condition: Constipation - Functional
Intervention: Drug: Lubiprostone
39 Recruiting Pediatric Obesity Weight Evaluation Registry (POWER) Study
Conditions: Overweight;   Obesity
40 Recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years